The Medicare Prescription Payment Plan, usually shortened to M3P, was created by section 11202 of the Inflation Reduction Act and went live on January 1, 2025. It is the reason a pharmacy can hand you a $600 prescription and charge you nothing at the counter.
It is also one of the most misunderstood benefits in Medicare, because the thing people assume it does is exactly the thing it does not do. Every figure below was verified on September 6, 2026 against CMS guidance documents and Medicare.gov’s own program pages.
What the Payment Plan Actually Does
M3P is a cash-flow tool. When you opt in, you stop paying the pharmacy for Part D covered drugs. Your plan pays the pharmacy, then sends you a monthly bill spreading your out-of-pocket share across the months left in the calendar year.
CMS states the limit of the benefit in one sentence in its official fact sheet: this option “might help you manage your monthly expenses, but it doesn’t save you money or lower your drug costs.” Your annual total is identical either way.
What actually caps your spending is a separate provision of the same law. For 2026 the Part D annual out-of-pocket threshold is $2,100, per the CMS Final CY 2026 Part D Redesign Program Instructions, and that ceiling applies to everyone with Medicare drug coverage whether or not they use the payment plan. The 2026 standard Part D deductible is $615.
CMS has already published the 2027 figures. In the CY 2027 Rate Announcement dated April 6, 2026, Table V-6 sets the 2027 defined standard deductible at $700 and the 2027 annual out-of-pocket threshold at $2,400. Both parameters are indexed each year to the annual percentage increase in average Part D drug spending, so the amount M3P can spread will keep climbing.
How the Monthly Cap Is Calculated
The statute prescribes two different formulas, and the first month is the odd one.
First month: the annual out-of-pocket threshold, minus any Part D out-of-pocket costs you already incurred that year before opting in, divided by the number of months remaining in the plan year (including the current month). Your plan must bill you the lesser of that ceiling or your actual costs.
Every month after: any balance not yet billed to you, plus new out-of-pocket costs incurred that month, divided by the months remaining.
Two consequences follow. Joining in January with a clean slate puts your first-month ceiling at $2,100 divided by 12, or $175. And because the denominator shrinks all year while new prescriptions keep landing in the numerator, your bill generally rises month over month.
Here is CMS’s own 2026 worked example, from the September 2025 program fact sheet. Someone with $525 a month in out-of-pocket drug costs who joins in January hits the $2,100 cap in April and then owes nothing new for the rest of the year.
| Month | Drug cost without the plan | Bill with the plan | What is happening |
|---|---|---|---|
| January | $525 | $175 | First-month formula: ($2,100 - $0) / 12 |
| February | $525 | $79.55 | ($350 balance + $525) / 11 |
| March | $525 | $132.05 | ($795.45 + $525) / 10 |
| April | $525 | $190.38 | ($1,188.40 + $525) / 9, and the $2,100 cap is reached |
| May through December | $0 | $190.38 each month | Paying down the balance, no new costs |
| Total | $2,100 | $2,100 | Identical annual total |
Note that January is the only month where this person pays less than they would have. The plan bought them a $350 deferral in month one and then charged it back at roughly $190 a month for the rest of the year.
What It Costs
Nothing. CMS prohibits plan sponsors from charging participants any fee, including late fees, interest payments, and payment mechanism fees. The prohibition extends to third parties the sponsor contracts with. If a plan’s billing error causes you to incur a bank overdraft fee, CMS expects the sponsor to work with you to reconcile it.
Participation is voluntary and every Medicare drug plan and Medicare Advantage plan with drug coverage is required by statute to offer it. KFF confirms the same mandate in its Medicare open enrollment FAQs.
Who Benefits and Who Is Made Worse Off
Medicare.gov’s guidance is unusually direct about the second group. You are most likely to benefit if you have high drug costs early in the calendar year, and joining before September gives you more months to spread them across.
Medicare lists five situations where this option may not be the right choice:
- Your yearly drug costs are low
- Your drug costs are about the same every month
- You are considering signing up after September
- You get or qualify for Extra Help or a Medicare Savings Program
- You get help from a State Pharmaceutical Assistance Program, a manufacturer coupon program, or other coverage
The steady-spender case is the clearest trap. CMS’s second published example follows someone paying $80 a month, $960 for the year. Under M3P they pay $80 in January, then $7.27 in February, and the bill climbs every month until it reaches $241.59 in December. CMS’s own comment on that example: they “might not benefit from using this payment option due to the higher payments that start in September.”
If your problem is the size of the bill rather than its timing, the payment plan is the wrong tool. Look at prescription assistance programs, at discount card pricing versus your plan’s copay, and at Cost Plus Drugs pricing instead. Cash prices outside your plan do not count toward the $2,100 cap, so that comparison matters.
Missing a Payment
This is the real risk, and it is the part most summaries skip.
Your plan sponsor must give you a grace period of at least two months, starting the first day of the month for which the balance is unpaid, or the first day of the month after the payment was requested, whichever is later. If you have not paid by the end of it, the sponsor is required by statute to terminate your participation and must send a termination notice within three business days.
Termination does not erase the debt. You still owe the balance in full, and you can pay it in a lump sum or ask to be billed monthly. Interest and late fees remain prohibited even when your payment is late.
Two protections matter here. Your plan cannot disenroll you from your Part D drug coverage for failing to pay an M3P bill, and it cannot refuse you future Part D enrollment on that basis. But it can bar you from rejoining the payment plan in a later year while you still owe that sponsor an overdue balance, and that preclusion can extend past the immediately following year across every plan the same parent organization offers.
You can be reinstated if you show good cause, meaning the failure was due to circumstances you could not control or reasonably foresee, and you pay all overdue amounts. CMS’s listed examples include serious illness or hospitalization covering a significant portion of the grace period, home damage from a fire or natural disaster, and a declared federal or state emergency. Sponsors may also reinstate you at their discretion once you pay off the balance even without good cause.
Medicare’s standing instruction if money is tight: always pay your plan premium first, because that is the payment that keeps your drug coverage. If premiums themselves are the strain, see how Medicare premium billing and Easy Pay work.
How to Opt In
Contact your drug plan or Medicare Advantage plan directly, by phone or through its website, at any point in the calendar year. There is no central Medicare sign-up. Your plan sends a confirmation letter, then notifies your pharmacy automatically so you pay $0 at the counter.
You may also meet the program at the pharmacy first. CMS requires plans and pharmacies to hand you a standardized “Likely to Benefit Notice” when a single prescription carries $600 or more in out-of-pocket cost. CMS set that $600 single-prescription threshold in its final part one guidance for 2025, choosing it because it identifies people with roughly a 98 percent likelihood of benefiting, and has not published a different figure since. The notice is an offer, not an enrollment.
One quirk of the first-month formula: if you opt in late in the year, your first-month ceiling can exceed the cost of the prescription that triggered the notice, in which case you are billed the whole thing in month one anyway. CMS flags this scenario directly in its part two guidance.
Participation renews automatically each January unless you switch plans or opt out. If you change plans, your M3P participation ends and you have to ask the new plan to start it again. You can leave at any time, and leaving does not affect your drug coverage.
The Bottom Line
The Medicare Prescription Payment Plan is a zero-interest, zero-fee installment option on money you already owe, capped at $2,100 in 2026 and $2,400 in 2027. It is genuinely useful if a specialty drug would otherwise wipe out a month’s budget in January, and close to useless if your spending is flat or small.
Before you use it, check whether you qualify for a program that reduces the bill rather than reschedules it. Extra Help, Medicare Savings Programs, and manufacturer assistance all shrink the number. If a Part B or Part D surcharge is what is squeezing you, that is a separate fight with its own process at the IRMAA appeal. And if the pressure is coming from medical bills rather than drug costs, start with medical bill assistance programs.